Komori
Earnings presentation4151Kyowa Kirin Co.,Ltd.Pharmaceuticals

Earnings Briefing Supplementary Materials — Third Quarter of the Fiscal Year Ending December 2026

For the cumulative third quarter of the fiscal year ending December 2026, revenue increased 10% year on year, core operating profit increased 47%, and profit for the period increased 59%. The full-year forecasts, including revenue of ¥520 billion and core operating profit of ¥130 billion, were maintained, and the actual sales results by product and region and the progress of the development pipeline were updated.

Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
355
¥100 million (year-on-year increase in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportQ3 FY20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,849 hundred million+10.0%
Operating profit¥970 100 million +47.0%core operating profit
Ordinary income¥647 100 million +35.0%profit before tax for the quarter
Net income¥517 100 million +59.0%profit for the year
Selling, general and administrative expenses¥1,237 100 million shown as negative
Gross Profit Margin
Rate74.9
Operating profit margin
Rate25.2
Results for the three months of the current quarter
Revenue
¥1,213 hundred million+2.0%
Core operating profit
¥308 hundred million+5.0%
Profit before tax for the quarter
¥273 hundred million+5.0%
Quarterly profit
¥211 hundred million+29.0%
Full-year earnings forecast
Revenue
¥5,200 hundred million
Costs of sales
¥-1,320 hundred million
Gross profit
¥3,880 hundred million
Selling, general and administrative expenses
¥-1,630 hundred million
Research and development expenses
¥-950 hundred million
Core operating profit
¥1,300 hundred million
Pretax profit
¥950 hundred million
Profit for the period
¥750 hundred million
Core profit for the period
¥1,030 hundred million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Revenue74%
Selling, general and administrative expenses76%
Research and development expenses71%
Core operating profit75%
Pretax profit68%
Profit for the period69%
Core profit for the period75%
Revenue by regional headquarters company
Japan75%
North America70%
EMEA80%
Other76%
Revenue from major products
Products and merchandise74%
Crysvita73%
Poteligeo71%
Libmeldy／Lenmeldy73%
Nourianz89%
Fozebel61%
Duvroq79%
Nesp73%
G-Lasta65%
Romiplate79%
Orkedia74%
Technology income74%
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
US dollar
January–September 2026 actuals159 USD/JPY
2026 full-year forecast150 USD/JPY
British pound
January–September 2026 actuals213 GBP/JPY
2026 full-year forecast205 GBP/JPY
Euro
January–September 2026 actuals185 EUR/JPY
2026 full-year forecast180 EUR/JPY
New initiatives
  • Development pipeline updated as of 30 September 2026
  • For KK4408, initiated dosing of the first patient in a Phase I/II trial for autoimmune diseases in Japan on 6 October 2026
Key KPIsA metric the company considers important as a management benchmark.
  • Overseas Revenue Mix77 %
  • R&D expense ratio17.6 %
    Year on year against the same period last year22.0% in the same period of the previous year
  • ROE7.7 %
  • ROE (three-year average)8.3 %
  • DOE3.8 %
Segment results
Japan
Revenue
¥837 hundred million
Year-on-year change in amount-60
North America
Revenue
¥1,485 hundred million
Year-on-year change in amount186
EMEA
Revenue
¥628 hundred million
Year-on-year change in amount4
Other
Revenue
¥900 hundred million
Year-on-year change in amount225
Financial targets
ROE
Actual results7.7 %
Target8.2%
ROE (three-year average)
Actual results8.3 %
TargetMid-7% range, 4% or more
DOE
Actual results3.8 %
Target4.1%, progressive dividend policy
Number of employees
Number of Employees5,117 people
Change during the period-395 people
Capital expenditures
¥287 100 million cumulative capital investment and investment in intangible assets from January to September 2026
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredQ3 FY2026
Net Sales¥3,849 hundred million (YoY +10.0%)
Operating profit¥970 100 million (core operating profit) (YoY +47.0%)
Ordinary income¥647 100 million (profit before tax for the quarter) (YoY +35.0%)
Net income¥517 100 million (profit for the year) (YoY +59.0%)
Gross Profit MarginRate 74.9 / Year-on-year change (points) Not disclosed
Operating profit marginRate 25.2 / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses¥1,237 100 million (shown as negative)
Results for the three months of the current quarterRevenue ¥1,213 hundred million (YoY +2.0%) / Core operating profit ¥308 hundred million (YoY +5.0%) / Profit before tax for the quarter ¥273 hundred million (YoY +5.0%) / Quarterly profit ¥211 hundred million (YoY +29.0%)
Full-year earnings forecastRevenue ¥5,200 hundred million / Costs of sales ¥-1,320 hundred million / Gross profit ¥3,880 hundred million / Selling, general and administrative expenses ¥-1,630 hundred million / Research and development expenses ¥-950 hundred million / Core operating profit ¥1,300 hundred million / Pretax profit ¥950 hundred million / Profit for the period ¥750 hundred million / Core profit for the period ¥1,030 hundred million
Progress against full-year forecastRevenue 74% / Selling, general and administrative expenses 76% / Research and development expenses 71% / Core operating profit 75% / Pretax profit 68% / Profit for the period 69% / Core profit for the period 75% / Revenue by regional headquarters company Japan 75% / North America 70% / EMEA 80% / Other 76% / Revenue from major products Products and merchandise 74% / Crysvita 73% / Poteligeo 71% / Libmeldy／Lenmeldy 73% / Nourianz 89% / Fozebel 61% / Duvroq 79% / Nesp 73% / G-Lasta 65% / Romiplate 79% / Orkedia 74% / Technology income 74%
Segment resultsJapan Revenue ¥837 hundred million / Year-on-year change in amount -60 / North America Revenue ¥1,485 hundred million / Year-on-year change in amount 186 / EMEA Revenue ¥628 hundred million / Year-on-year change in amount 4 / Other Revenue ¥900 hundred million / Year-on-year change in amount 225
Key KPIsIndicator name Overseas Revenue Mix / Value 77 % / Year on year against the same period last year Not disclosed, Indicator name R&D expense ratio / Value 17.6 % / Year on year against the same period last year 22.0% in the same period of the previous year, Indicator name ROE / Value 7.7 % / Year on year against the same period last year Not disclosed, Indicator name ROE (three-year average) / Value 8.3 % / Year on year against the same period last year Not disclosed, Indicator name DOE / Value 3.8 % / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees 5,117 people / Change during the period -395 people
Assumptions Underlying the Business OutlookUS dollar January–September 2026 actuals 159 USD/JPY / 2026 full-year forecast 150 USD/JPY / British pound January–September 2026 actuals 213 GBP/JPY / 2026 full-year forecast 205 GBP/JPY / Euro January–September 2026 actuals 185 EUR/JPY / 2026 full-year forecast 180 EUR/JPY
Financial targetsROE Actual results 7.7 % / Target 8.2% / ROE (three-year average) Actual results 8.3 % / Target Mid-7% range, 4% or more / DOE Actual results 3.8 % / Target 4.1%, progressive dividend policy
Capital expenditures¥287 100 million (cumulative capital investment and investment in intangible assets from January to September 2026)
New initiativesDevelopment pipeline updated as of 30 September 2026, For KK4408, initiated dosing of the first patient in a Phase I/II trial for autoimmune diseases in Japan on 6 October 2026
Items this document does not state (12)
Self-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The materials do not explain the reasons for changes in performance in prose or by monetary amount for each factor. They do include the monetary amounts of changes in sales by region and product.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Earnings Briefing Supplementary Materials — Third Quarter of the Fiscal Year Ending December 2026 | Kyowa Kirin Co.,Ltd. (4151) timely disclosure | Komori